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Labeling Efficacy of Superparamagnetic
Iron Oxide Nanoparticles to Human
Neural Stem Cells: Comparison of
Ferumoxides, Monocrystalline Iron Oxide,
Cross-linked Iron Oxide (CLIO)-NH2 and
tat-CLIO
Objective: We wanted to compare the human neural stem cell (hNSC) labeling
efficacy of different superparamagnetic iron oxide nanoparticles (SPIONs),
namely, ferumoxides, monocrystalline iron oxide (MION), cross-linked iron oxide
(CLIO)-NH2 and tat-CLIO.
Materials and Methods: The hNSCs (5 10
5 HB1F3 cells/ml) were incubated
for 24 hr in cell culture media that contained 25  g/ml of ferumoxides, MION or
CLIO-NH2, and with or without poly-L-lysine (PLL) and tat-CLIO. The cellular iron
uptake was analyzed qualitatively with using a light microscope and this was
quantified via atomic absorption spectrophotometry. The visibility of the labeled
cells was assessed with MR imaging.
Results: The incorporation of SPIONs into the hNSCs did not affect the cellular
proliferations and viabilities. The hNSCs labeled with tat-CLIO showed the
longest retention, up to 72 hr, and they contained 2.15 0.3 pg iron/cell, which
are 59 fold, 430 fold and six fold more incorporated iron than that of the hNSCs
labeled with ferumoxides, MION or CLIO-NH2, respectively. However, when PLL
was added, the incorporation of ferumoxides, MION or CLIO-NH2 into the hNSCs
was comparable to that of tat-CLIO.  
Conclusion: For MR imaging, hNSCs can be efficiently labeled with tat-CLIO
alone or with a combination of ferumoxides, MION, CLIO-NH2 and the transfec-
tion agent PLL. 
uman neural stem cells (hNSCs) can be used to replace dead tissue in
patients suffering with Alzheimer’s disease, amyotrophic lateral sclerosis,
Huntington’s disease, stroke and spinal cord injury (1, 2). There is a
growing interest in in vivo visualization of transplanted cells with using noninvasive
techniques such as magnetic resonance (MR) imaging. The development of an
appropriate MR imaging technique with optimized cell labeling conditions will be
useful to monitor the effectiveness of cell implantation, homing and differentiation (3).   
Superparamagnetic iron oxide nanoparticles (SPIONs) have been used for cell
labeling agents in both preclinical and clinical settings. Ferumoxide (AMI-25), a
standard SPION agent, is clinically approved and commercially available (4 6). It is
coated with dextran and has a hydrodynamic diameter of approximately 100 nm.
Monocrystalline iron oxides (MIONs) are smaller (28 nm) than the standard SPIONs so
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Hthat they can easily pass through the capillary endothelium.
The cross-linked iron oxide (CLIO)-NH2 is a modified form
of MIONs, and it had the same biophysical properties as
MIONs (7). In terms of the particle size, MIONs or CLIO-
NH2 might be more useful for performing cellular and
molecular MR imaging. However, many cell types, includ-
ing most stem cells, do not take up appreciable amounts of
unmodified iron oxide preparations (8 11). One solution
has been to modify the surface of the particles with
monoclonal antibody or tat-peptide (12), which may result
in increased internalization of the particles. Tat-peptide is
purified from the human immunodeficiency virus (HIV) tat-
peptide, and it carries both a transmembrane and nuclear
localization signal within its sequence; it is capable of
translocating exogeneous molecules into cells (13 15). The
other approach is to use a transfection agent such as
superfect, lipofectamine or poly-L-lysine (PLL) (16 19).
Recent studies have demonstrated that ferumoxides or
MIONs with using the transfection agent PLL are suitable
for labeling human stem cells (6). To the best of our
knowledge, no study has been performed that’s compared
the cell labeling efficacy of surface modified SPIONs with
using transfection agents. Thus, the purpose of this study
was to compare the hNSC labeling efficacy of different
SPIONs, namely, ferumoxides, MION, CLIO-NH2 and tat-
CLIO.
MATERIALS AND METHODS
Cell Line and Culture Conditions
HB1F3 is a commercially available hNSC line (1), and
this was a gift from a donor (Ajou University, Suwon,
Korea). The cells were grown in a humidified 5% CO2
atmosphere at 37 in Dulbecco’s modified Eagle medium
(Sigma, St. Louis, MO) that was supplemented with 5%
fetal bovine serum, 100  g/ml penicillin, 100 U/ml strepto-
mycin (Sigma), 5% horse serum, 50  g/ml recombinant
human epidermal growth factor (PeproTech Inc., Rocky
Hill, NJ), and 1  l/ml recombinant human fibroblast
growth factor-basic (PeproTech Inc.). 
Iron Oxide Labeling
HB1F3 cells (5 10
5 cell/ml) were separately labeled for
24 hours with using the four different types of SPIONs at
25  g/ml, i.e., ferumoxides (Feridex IV; Advanced
Magnetics, Cambridge, MA), MION-47 (The Center for
Molecular Imaging Research, Massachusetts General
Hospital, Charlestown, MA), CLIO-NH2 and tat-CLIO (20).
The CLIO-NH2 was synthesized by cross-linking MION in a
strong base containing epichlorohydrin, and by reacting the
obtained product with ammonia. Tat-CLIO was synthesized
with using CLIO and tat-peptide, and the tat-peptide was
purified from the HIV tat-peptide. The synthesized CLIO-
NH2 and tat-CLIO had the same chemical properties as
previously reported (7). After 24 hr, the agents were
washed out with phosphate-buffered saline (PBS) and the
cells were washed three times with PBS. In order to detect
the iron in the cells after labeling, the cells were fixed with
paraformaldehyde and stored at 4 .
A transfection agent PLL (Sigma) at 0.25, 0.5, 1 or 2 
g/ml was mixed with ferumoxides, MION-47 or CLIO-
NH2 for 60 minutes in a cell culture medium at room
temperature on a rotating shaker, and these mixed media
were then used to label the HB1F3 cells. 
Retention of Iron Oxides in the Cells
In order to investigate retention of iron oxide in HB1F3
cells after in vitro culture, the iron labeled cells were
incubated for up to 72 hr in cell culture media. After
incubating for 0, 6, 24, 30, 48 or 72 hr, the cultured cells
were fixed with 4% paraformaldehyde and stored at 4
until they were used for Prussian blue staining (PBS).
Prussian Blue Staining
The fixed HB1F3 cells were washed three times with
PBS, incubated for 30 min with 5% potassium
ferrocyanide in 5% hydrochloric acid, rewashed and then
counterstained with nuclear fast red. Representative
labeled cells were examined under a light microscope to
determine the intracellular iron oxide distributions. 
Cell Proliferation and Viability
The proliferative activities and the viabilities of the iron
oxide labeled HB1F3 cells were evaluated by performing
long-term (10 days) cell proliferation assays and trypan
blue exclusion testing, respectively. The proliferative
activities after the magnetic labeling were confirmed by
noting the increased amount of cells during the periods of
culture time compared with the control. The cell viability
value, as compared to a control cell group, was estimated
to be 100%. 
Measurement of the Iron Contents
The iron contents of the labeled HB1F3 cells were
determined by performing atomic absorption spectropho-
tometry (SpectrAA 800; Varian, Walnut Creek, CA).
Briefly, cell suspensions (4 10
6 cells/
2 ml PBS) were
completely digested in a mixture (2.4 ml) of 35%
hydrochloric acid (1.8 ml) and 65% nitric acid (0.6 ml) by
heating them for at least three hours at 60 . They were
then diluted to a volume of 10 ml with destabilized water
and this was next filtered. The iron concentrations in the
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obtained with using ferrous chloride calibration standards
that contained 0, 250, 500 or 1,000  g/L of iron in the
above-mentioned mixture. The iron contents were also
confirmed by performing ferrozine-based spectrophoto-
metric assays with using triplicate samples of the acid-
digested cell suspensions. The average iron contents per
cell were calculated as mean values divided by the number
of cells in each sample. 
MR Imaging
Phantom cell suspensions (312, 625, 1,250, 2,500, 5,000
and 10,000 cells/ l) were prepared in 2% agarose gel. MR
imaging of the phantoms was performed under a standard
knee coil and with using a 1.5 T MR imager (Signa
Horizon; GE Medical Systems, Milwaukee, WI) to obtain
the T2-axial images. The sequence parameters were a
repetition time = 5,000 ms, an effective echo time = 90 ms,
a field of view = 120 120 mm, a flip angle = 90 , a
matrix = 256 160, a slice thickness = 2.0 mm a slice
separation = 0 mm and the number of excitations = 3.0. 
The T2 and T2* values were measured by using the
conventional spin-echo (TR/TE = 2000 ms/10, 15, 20, 25,
30, 40, 50, 60 and 70 ms) and gradient-echo sequences
(TR/TE = 1000 ms/4, 11, 18, 25, 32 and 39 ms) with one
echo for each sequence, while varying the TE. The T2 and
T2* values were calculated by fitting the decreased signal
intensities with the increasing TEs into a mono-exponential
function. The T1 was determined by using the inversion-
recovery fast spin-echo sequences (TR/TE/TI =
2200/18/50, 100, 200, 500, 800, 1200, 2100 ms) while
varying the TI and keeping the TR and TE constant. The
image intensities with the various TIs were proportional to
|[1 (1 k)exp( TI/T1)]Mo| and T1 was measured using a
least squares fit of the image intensities in this equation
(25).
Statistical Analysis
All the data is presented as means standard deviations.
The data was statistically processed using the Mann-
Whitney test. For all the tests, p values of < 0.05 were
considered to indicate statistical significance. All the
calculations were performed using commercially available
statistical software (GraphPad Prism, version 4; GraphPad,
San Diego, CA). 
RESULTS
Labeling 
The HB1F3 cells exposed to the ferumoxides, MION-47,
CLIO-NH2 or tat-CLIO showed intracellular uptake of the
iron oxide (Fig. 1). However, no intracellular uptake of the
iron oxide was detected in cells incubated with MION-47. 
Retention
The number of iron-containing cells decreased as the
incubation time increased for all the SPION-labeled cells
(Fig. 2). The cells loaded with tat-CLIO showed a greater
numbers of blue stained cells at all time points compared
to the ferumoxides and the CLIO-NH2 labeled cells. The
ferumoxide-exposed cells and the CLIO-NH2 exposed cells
showed iron labeling until 24 48 hr, whereas iron-
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Fig.1. Photomicrographs of the hNSCs
treated for 24 hr with ferumoxides (A),
MION-47 (B), CLIO-NH2 (C) or tat-CLIO
(D) at 25  g/ml. The intracellular uptake
of iron oxide nanoparticles (arrows) is
seen in cells exposed to ferumoxides (A),
CLIO-NH2 (C) or tat-CLIO (D). However,
no intracellular uptake of iron oxide was
found for the cells incubated with MION-
47 (B). (Prussian blue stain, objective
magnification:  40)
CD
ABcontaining cells were visible after 72 hr for the tat-CLIO
exposed cells. However, more than 90% of the HB1F3
cells labeled with tat-CLIO were unlabeled after 48 hr of
incubation. 
Viability and Proliferation
The average viability of the control cells, as determined
by trypan blue exclusion assay, was 100 4.5%. The
viable percentage of the ferumoxide-labeled, MION-47
Song et al.
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Fig. 3. Photomicrographs of hNSCs treated for 24 hr with three different SPIONs (ferumoxides, MION-47 or CLIO-NH2) at 25  g/ml in the
presence of different doses of PLL. As the PLL concentration increased in the media from 0.25  g/ml to 2  g/ml, more iron oxide
nanoparticles are seen inside the labeled cells. (Prussian blue stain, objective magnification:  40)
Fig. 2. Retention of SPIONs in hNSCs. Iron oxide nanoparticles (arrows) are seen within the ferumoxides labeled cells and the CLIO-
NH2 labeled cells for up to 24 and 48 hr, respectively and inside the tat-CLIO labeled cells for up to 72 hr. (Prussian blue stain, objective
magnification:  40)
PLL
+
Ferumoxides
CLIO-NH2
Tat-CLIO
Ferumoxides
MION-47
CLIO-NH2
0.25  g/ml 0.5  g/ml 1  g/ml 2  g/ml
6h 24h 30h 48h 72hlabeled, CLIO-NH2 labeled or tat-CLIO-labeled HB1F3
cells versus the unlabeled control cells was 105 3.9, 101
5.1, 101 2.5 and 95 6.5, respectively. The cells
exposed to these SPIONs showed no differences of viabil-
ity versus the unlabeled cells, and there was no effect on
the proliferative capability of the cells labeled with all four
SPIONs during 10 days of culture. 
Increased Intracellular Iron Uptake Induced by Poly-
L-Lysine
Prussian blue staining of the SPION-exposed cells with
PLL revealed a dose-dependent increase of the iron oxide
uptake into the cells (Fig. 3). Almost 100% of the cells
were labeled with iron oxide when the HB1F3 cells were
incubated in SPION media that contained 2  g/ml PLL. So,
the concentration 2  g/ml of PLL was selected to transfect
iron oxide into the cells. The viabilities and proliferations
of the SPION exposed cells with using PLL were similar to
those of the unlabeled control cells.
Iron Contents with and without Poly-L-Lysine
Atomic absorption spectrophotometry revealed the
highest iron incorporation in the tat-CLIO-exposed cells (2
0.3 pg/cell) and the lowest in the MION-47-exposed cells
Superparamagnetic Iron Oxide Nanoparticles to Human Neural Stem Cells
Korean J Radiol 8(5), October 2007 369
Fig. 4. Quantitative iron determination by an atomic absorption
spectrophotometer. The graph shows the highest iron incorpora-
tion in the tat-CLIO labeled cells (2.15 0.3 pg/cell) and the
lowest in the MION-47 labeled cells (0.005 pg/cell) in absence of
PLL (black bars). With PLL (white bars), the iron content in the
ferumoxides labeled, MION-47 labeled or CLIO-NH2 labeled cells
increased to 1.08 0.07 pg/cell, 1.01 0.02 pg/cell and 2.24
0.17 pg/cell, respectively, which are 27 fold, 202 fold and 7-fold
greater uptakes, respectively, compared with the cells without
using PLL. The cells labeled with CLIO-NH2 in the presence of
PLL show a similar intracellular iron content as the tat-CLIO-
labeled cells (p > 0.1). 
Note. w/o = without, w = with, ns = statistically non-significant
Fig. 5. Gradient-echo T2-weighted MR
images of the phantoms with different
cell numbers (i.e., 312, 625, 1,250,
2,500, 5,000 and 10,000 cells/ l). MR
scans were performed at different time
points with (A) the control, the MION-47
treated cells and the MION-47+PLL
treated cells, (B) the ferumoxides
treated cells and the ferumoxides with
PLL treated cells, and (C) the CLIO-NH2
treated cells, the CLIO-NH2 with PLL
treated cells and the tat-CLIO treated
cells. In the absence of PLL, the
phantoms with more than 1,250 cells/ l
of the tat-CLIO-labeled cells show a
decreased signal on the T2-weighted
MR images. For the ferumoxides treated
cells and the CLIO-NH2 treated cells,
the phantoms with more than 2,500
cells/ l show a visibly decreased signal
without PLL. With PLL, a decreased
signal is found in the phantoms with the
ferumoxides treated cells, in the
phantoms with the MION-47 treated
cells and in the phantoms with the
CLIO-NH2 treated cells, with 625 1,250
cells/ l respectively. ‘Control’ represents
the MR image of the phantom with the
non-labeled control cells.
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w. PLL(0.005 pg/cell) (Fig. 4). The ferumoxides and CLIO-NH2
showed 0.04 0.01 and 0.34 0.07 pg of iron/cell, respec-
tively. The tat-CLIO-labeled cells showed 59-fold, 430-fold
and 6-fold higher uptakes than did the ferumoxide-labeled,
MION-47 labeled and CLIO-NH2 labeled cells, respec-
tively.
With using PLL, the iron content in the ferumoxide-
labeled, MION-47-labeled and CLIO-NH2-labeled cells
increased to 1.1 0.07 pg/cell, 1.0 0.02 pg/cell and 2.2
0.17 pg/cell, which are 27 fold, 202 fold and 7-fold
uptakes, respectively, compared to the comparably treated
cells without PLL. The cells treated with CLIO-NH2 and
PLL showed a similar intracellular iron content as the tat-
CLIO-labeled cells (p > 0.1) (Fig. 4). 
MR Imaging
Phantoms with more than 1,250 cells/ l of tat-CLIO-
labeled cells were visualized on the T2-weighted MR
images (Fig. 5). For the ferumoxides and CLIO-NH2, the
phantoms with more than 2,500 cells/ l and 10,000 cells/ l
had a visibly decreased signal when not using PLL. With
using PLL, a decreased signal was found in phantoms with
625 1,250 cells/ l with the ferumoxide labeled, MION-47
labeled and CLIO-NH2 labeled cells. 
Table 1 shows the T1, T2, and T2* values that were
measured in the phantoms with 1,250 cells/ l of the differ-
ent SPIONs. A stronger susceptibility effect was found in
the cells labeled with tat-CLIO (a T2* value of 18 2
msec) than that of the cells labeled with ferumoxides (49
2 msec), MION-47 (57 2 msec) or CLIO-NH2 (32 3
msec). However, in the presence of PLL, the strongest
susceptibility was obtained for the ferumoxide labeled cells
(13 1 msec). In all cases, mono-exponential signal
intensity decreases were found that allowed very
unambiguous determination of the T2 and T2* values. 
DISCUSSION
Of the four different SPIONs, i.e., ferumoxides, MION-
47, CLIO-NH2 and tat-CLIO, we found that tat-CLIO, a
SPION with its surface modified with transmembrane
translocation signals, was the most efficient agent for
introducing iron oxide into hNSCs when these agents were
added to cell culture media alone. However, ferumoxides,
which are a clinically approved contrast media, were as
efficient as tat-CLIO for introducing iron oxide into the
hNSCs when PLL was used as a supportive transfection
agent during the cell incubation. Labeling cells by means of
simple incubation with ferumoxides is more practical than
using the complicated surface modification method. 
Our results are consistent with other previous studies;
the previous reports showed that transfection agents
improve the labeling efficiency of ferumoxides or MION to
stem cells and to other mammalian cells (6, 16 22). In a
study by Jendelova et al. (5), ferumoxides were incorpo-
rated into mouse embryonic stem cells and rat mesenchy-
mal stem cells, without the aid of any transfection agent,
when the cells were incubated at 112.4 mg/ml for three
passages or for five days, respectively. Yet in our study,
only 17% tagging of the hNSCs was obtained at a lower
concentration (25  g/ml) of ferumoxides and after a
shorter incubation time (24 hrs). Although some studies
have used ferumoxides or MION alone to label cells, they
were not efficiently taken up by cells, except for the
phagocytic cells, or the cells were put in higher concentra-
tions of iron. We found that the MION-47 treated hNSCs
were not labeled either, and that the number of CLIO-NH2
labeled cells was less than the tat-CLIO labeled cells, like a
previous report (13). For the carboxydextran-coated
SPIONs, a larger particle size resulted in improved cellular
uptake (65 nm, 4.4  g 0.08 Fe per 100,000 cells; 17 nm,
2.1  g 0.06 Fe per 100,000 cells; p < 0.05) (18).
The transfection agent PLL has a relatively small
toxic/efficacious ratio, with PLL concentrations as low as
10 mg/ml in media causing significant cell death (16).
Ferumoxides complexed to PLL effectively label cells, but
residual Fe-PLL complexes may remain on the surface of
the cells or they cause cells to clump together in the final
Song et al.
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Table 1. The T1-, T2- and T2*- Values Measured in the Phantoms with 1,250 cells/ l of Different Superparamagnetic Iron Oxide
Nanoparticles
T1 T2 T2*(ms) T1 T2 T2*(ms)
Control 794 27 46 54 2 3
Ferumoxides 733 58 50 44 9 2 Ferumoxides PLL 588 94 32 12 13 1
MION-47 736 54 56 75 7 2 MION-47 PLL 604 27 29 10 18 2
CLIO-NH2 630 14 39 53 2 3 CLIO-NH2 PLL 643 12 23 61 8 2
Tat-CLIO 613 16 27 71 8 2
Note. Data are the means with standard deviations. ms = msec, MION = monocrystalline iron oxide, CLIO= cross-linked iron oxide, 
PLL = poly-L-lysinecell preparation prior to infusion. A recent report indicated
that labeling mesenchymal stem cells with ferumoxides-
PLL complexes inhibited the chondrogenic differentiation
capacity of mesenchymal stem cells (23). In contrast,
labeling cells with ferumoxides-protamine sulfate
complexes did not alter the viability and functional
capacity of a variety of cell types (24). In our study,
SPIONS, including tat-CLIO, showed no adverse effect on
the cell proliferations and viabilities. However, we did not
check the effect on cell differentiation and so further
studies on these issues are necessary.
In conclusion, our study indicates that hNSCs can be
safely and efficiently labeled for MR imaging with using
either tat-CLIO alone or a combination of ferumoxides,
MION-47 and CLIO-NH2 and the transfection agent PLL.
These labeling methods could be used to noninvasively
track hNSCs. 
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